Normax Biomed has launched a capital raise campaign for up to £15 million in Series A funding for the deployment of Educated Antigen Receptor Therapy (EARTh) GMP Process for personalized mRNA cancer vaccine production in GMP clean room located in the Medical Technology Innovation Center (MTIF) at Nottingham Trent University Clifton Campus
May 13, 2024, 12:00 PM Greenwich Mean Time (GMT) – PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER.
Nottingham, UK – 13 May 2024 – Normax Biomed, a pioneering biotechnology company specializing in personalized mRNA immunotherapy, and Oyster Venture Partners, a leading investment advisory firm focused on high-growth life science companies, today announced a strategic partnership to raise up to £15 million in Series A funding, along side other associated initiatives to leverage the IP within Normax Biomed. This investment will support the establishment of the first-of-its-kind personalized mRNA cancer vaccine production facility at the Medical Technologies Innovation Facility (MTIF) located at Nottingham Trent University (NTU) Clifton Campus.
The facility will utilize Normax Biomed’s proprietary Educated Antigen Receptor Therapy (EARTh) GMP process, enabling the development of truly personalized precision (n=1) mRNA cancer vaccines tailored to each patient’s unique tumor profile. This groundbreaking approach promises to revolutionize cancer treatment by offering a more effective and targeted therapy, utilizing the bodies own immune system, with the potential for long-lasting remission for a lifetime of treatment of the patient, if needed.
“This partnership with Oyster Venture Partners marks a significant milestone for Normax Biomed,” said Peter A. Jensen, CEO of Normax. “Their expertise and network within the investment community will be invaluable as we work to bring our innovative EARTh GMP Process and Protocol technology to patients in need. Together, we can make a real difference in the fight against cancer. The strategic location at MTIF will enable Normax to leverage the expertise of leading researchers and clinicians, further accelerating the development and delivery of personalized mRNA cancer vaccines for cancer patients in the UK.”
“With a very strong, visionary and experienced team, and a strategic cooperation with MTIF at NTU, Normax is developing a revolutionary GMP process pipeline of personalized drug development technologies in combination with advanced artificial intelligence processing of patient data, for rapid delivery of mRNA vaccine immunotherapy for each cancer patient.” said Rupert Lewis, CEO at Oyster Venture Partners. “We are really excited to support Normax Biomed in its mission and Oyster is committed to work with Normax’s investors to bring this transformative product to market, with the potential to transform the lives of cancer patients in the UK, and the world.”
About Normax Biomed
The mission of Normax is to operate a mRNA immunotherapy sustainable business, with the ability to rapidly deliver vaccines in the event of an outbreak or pandemic: id.normaxbiomed.com
About Oyster Venture Partners
Oyster Venture Partners is a next generation corporate finance advisory firm supporting life science, healthcare and health-tech companies with their capital raising and sell-side/buy-side transactions. oysterventurepartners.com
About MTIF at NTU
MTIF provides state-of-the-art GMP clean room facilities and a collaborative environment for groundbreaking research and development in the medical technology sector. mtif.co.uk
